Abstract
Considerable evidence has been provided these last years for the involvement of the GABA-A receptor complex in memory processes. Compounds that enhance the action of GABA, such as benzodiazepines, impair memory processing. On the contrary, compounds that reduce the action of GABA, such as ß-CCM, pentylenetetrazol or picrotoxin, have the opposite action, that is : enhance memory processing. All these actions seem to focus mainly on the acquisition (learning) processes. Depending on the dose, the same compounds also have effects on anxiety and on seizuring. Benzodiazepines are well-known anxiolytic and anticonvulsant agents whereas compounds that reduce the action of GABA have been found to produce anxiogenic and convulsant actions. The GABA-A receptor complex might thus be the location of a possible link between a pathological state (epilepsy) and two normal functions (anxiety and learning). This link is likely to involve common genetic pathways. In the normal subject, these data also emphasize the idea that normal memory processing involves a moderate level of anxiety.
Keywords: gaba receptor complex, pentylenetetrazol, picrotoxin, learning, anxiety, epilepsy
Current Topics in Medicinal Chemistry
Title: GABA-A Receptor Complex and Memory Processes
Volume: 2 Issue: 8
Author(s): Georges Chapouthier and Patrice Venault
Affiliation:
Keywords: gaba receptor complex, pentylenetetrazol, picrotoxin, learning, anxiety, epilepsy
Abstract: Considerable evidence has been provided these last years for the involvement of the GABA-A receptor complex in memory processes. Compounds that enhance the action of GABA, such as benzodiazepines, impair memory processing. On the contrary, compounds that reduce the action of GABA, such as ß-CCM, pentylenetetrazol or picrotoxin, have the opposite action, that is : enhance memory processing. All these actions seem to focus mainly on the acquisition (learning) processes. Depending on the dose, the same compounds also have effects on anxiety and on seizuring. Benzodiazepines are well-known anxiolytic and anticonvulsant agents whereas compounds that reduce the action of GABA have been found to produce anxiogenic and convulsant actions. The GABA-A receptor complex might thus be the location of a possible link between a pathological state (epilepsy) and two normal functions (anxiety and learning). This link is likely to involve common genetic pathways. In the normal subject, these data also emphasize the idea that normal memory processing involves a moderate level of anxiety.
Export Options
About this article
Cite this article as:
Chapouthier Georges and Venault Patrice, GABA-A Receptor Complex and Memory Processes, Current Topics in Medicinal Chemistry 2002; 2 (8) . https://dx.doi.org/10.2174/1568026023393552
DOI https://dx.doi.org/10.2174/1568026023393552 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Clinical Impact of ABCB1 Polymorphisms on the Treatment of Psychiatric Diseases
Current Pharmaceutical Design The Sphingosine 1-Phosphate Signaling Pathway in Epilepsy: A Possible Role for the Immunomodulator Drug Fingolimod in Epilepsy Treatment
CNS & Neurological Disorders - Drug Targets Unusual Clinical Manifestations of the Antiphospholipid Syndrome
Current Rheumatology Reviews PET Tracers for Imaging of ABC Transporters at the Blood-Brain Barrier: Principles and Strategies
Current Pharmaceutical Design Gastrodia Elata Bl Attenuates Cocaine-Induced Conditioned Place Preference and Convulsion, but not Behavioral Sensitization in Mice: Importance of GABAA Receptors
Current Neuropharmacology Synthesis and Biological Potential Assessment of 2-Substituted Quinazolin-4(3<i>H</i>)-ones as Inhibitors of Phosphodiesterase-I and Carbonic Anhydrase-II
Medicinal Chemistry Melatonin Therapy of Pediatric Sleep Disorders: Recent Advances, Why it Works, Who are the Candidates and How to Treat
Current Pediatric Reviews Enzymes as Target Antigens of Liver-Specific Autoimmunity: The Case of Cytochromes P450s
Current Medicinal Chemistry Subject Index To Volume 12
Current Pharmaceutical Design Default Mode Network Connectivity and Related White Matter Disruption in Type 2 Diabetes Mellitus Patients Concurrent with Amnestic Mild Cognitive Impairment
Current Alzheimer Research Editorial [Hot topic: The Urokinase Receptor System as Strategic Therapeutic Target: Challenges for the 21st Century (Executive Guest Editor: Bernard Degryse)]
Current Pharmaceutical Design Structure-Activity Studies on Alpha-Conotoxins
Current Pharmaceutical Design Other Drugs Acting on Nervous System Associated with QT-Interval Prolongation
Current Drug Safety Diagnostic Biomarkers of Epilepsy
Current Pharmaceutical Biotechnology Anticonvulsant Activity Of Benzylamides Of Some Amino Acids And Heterocyclic Acids
Protein & Peptide Letters Anti-Vasopermeability Effects of PEDF in Retinal-Renal Disorders
Current Molecular Medicine The GABA A Receptor Subunits Heterologously Expressed in Xenopus Oocytes
Mini-Reviews in Medicinal Chemistry Development of Allosteric Modulators of Voltage-Gated Na<sup>+</sup> Channels: A Novel Approach for an Old Target
Current Topics in Medicinal Chemistry Formulation Strategies of Nano Lipid Carrier for Effective Brain Targeting of Anti-AD Drugs
Current Pharmaceutical Design Peripheral TRPV1 Receptors As Targets for Drug Development: New Molecules and Mechanisms
Current Pharmaceutical Design